Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis.

Debaters Andres Chang, MD, PhD, and Jean Louise Koff, MD, MS, led the verbal battle at the Debates and Didactics in Hematology and Oncology Conference held from July 25 to 28, 2024, in Sea Island, ...

Swiss pharma giant Roche has announced positive top-line results from the Phase III REGENCY study of Gazyva/Gazyvaro ...

Sep. 27, 2024 — Estrogens are known to drive tumor growth in breast cancer cells that carry its receptors, but a new study unexpectedly finds that estrogens play a role in fueling the growth of ...

To provide more robust evidence for clinicians, investigators analyzed the efficacy and safety of biologics in patients with lupus nephritis using meta-regression analyses that adjusted for trials’ ...

We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...

In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis ...

Roche announces positive results from phase III study of Gazyva/Gazyvaro in people with lupus nephritis: Basel Friday, September 27, 2024, 12:00 Hrs [IST] Roche announced positive ...

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN).

RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for ...

(IN BRIEF) Roche has announced positive results from its phase III REGENCY study, showing that its drug Gazyva®/Gazyvaro® (obinutuzumab) significantly outperformed standard therapy in treating active ...